-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Director Robert W. Postma Buys 750,000 Shares
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Director Robert W. Postma Buys 750,000 Shares
Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) Director Robert W. Postma bought 750,000 shares of the business's stock in a transaction on Tuesday, November 29th. The shares were acquired at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the transaction, the director now directly owns 5,000,000 shares in the company, valued at approximately $3,250,000. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
Alaunos Therapeutics Stock Performance
TCRT stock opened at $0.64 on Friday. The firm has a 50 day moving average of $1.25 and a 200 day moving average of $1.41. Alaunos Therapeutics, Inc. has a 52 week low of $0.41 and a 52 week high of $4.01.
Get Alaunos Therapeutics alerts:Wall Street Analyst Weigh In
Separately, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $3.00 price objective on shares of Alaunos Therapeutics in a research report on Tuesday, October 4th.
Institutional Trading of Alaunos Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. E Fund Management Co. Ltd. acquired a new stake in Alaunos Therapeutics in the 3rd quarter worth approximately $26,000. SevenBridge Financial Group LLC acquired a new stake in Alaunos Therapeutics in the 3rd quarter worth approximately $34,000. UBS Group AG boosted its stake in Alaunos Therapeutics by 7.6% in the 3rd quarter. UBS Group AG now owns 288,597 shares of the company's stock worth $496,000 after purchasing an additional 20,422 shares in the last quarter. Nicolet Advisory Services LLC acquired a new stake in Alaunos Therapeutics in the 2nd quarter worth approximately $30,000. Finally, BNP Paribas Arbitrage SNC boosted its stake in Alaunos Therapeutics by 67.5% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 58,847 shares of the company's stock worth $101,000 after purchasing an additional 23,704 shares in the last quarter. 33.88% of the stock is currently owned by institutional investors and hedge funds.About Alaunos Therapeutics
(Get Rating)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
Featured Articles
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) Director Robert W. Postma bought 750,000 shares of the business's stock in a transaction on Tuesday, November 29th. The shares were acquired at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the transaction, the director now directly owns 5,000,000 shares in the company, valued at approximately $3,250,000. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
納斯達克(代碼：TCRT-GET評級)董事在11月29日星期二的一筆交易中購買了750,000股該公司的股票。這些股票是以每股0.65美元的平均成本收購的，總交易額為487,500.00美元。交易完成後，董事現在直接擁有該公司500萬股股份，價值約325萬美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可在此超鏈接.
Alaunos Therapeutics Stock Performance
ALaunos治療公司股票表現
TCRT stock opened at $0.64 on Friday. The firm has a 50 day moving average of $1.25 and a 200 day moving average of $1.41. Alaunos Therapeutics, Inc. has a 52 week low of $0.41 and a 52 week high of $4.01.
TCRT股票週五開盤報0.64美元。該公司的50日移動均線切入位在1.25美元，200日移動均線切入位在1.41美元。ALaunos治療公司的股價為0.41美元，為52周低點，52周高點為4.01美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $3.00 price objective on shares of Alaunos Therapeutics in a research report on Tuesday, October 4th.
另外，富國銀行(Wells Fargo&Company)在10月4日(星期二)的一份研究報告中重申了“增持”評級，並對ALaunos治療公司的股票發佈了3.00美元的目標價。
Institutional Trading of Alaunos Therapeutics
ALaunos治療公司的機構交易
About Alaunos Therapeutics
ALaunos治療公司簡介
(Get Rating)
(獲取評級)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
ALaunos治療公司是一家專注於臨牀階段腫瘤學的細胞治療公司，開發採用TCR工程的T細胞療法。該公司開發了TCR文庫，該文庫對10個對突變的KRAS、TP53和EGFR產生反應的TCR進行了I/II期臨牀試驗，這些TCR文庫用於治療非小細胞肺癌、結直腸癌、子宮內膜癌、胰腺癌、卵巢癌和膽管癌；人類腫瘤抗原T細胞受體平臺HunTR；以及用於治療實體腫瘤的MBIL-15。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
- 免費獲取StockNews.com關於ALaunos治療公司(TCRT)的研究報告
- 福特在英國工廠加速生產電動汽車動力裝置
- 賣空者對馬倫汽車股票的看法仍然正確嗎？
- La-Z-Boy傾斜到更舒適的水平
- 蘋果會在年底前大漲嗎？
- 復甦集會是為SoFi而來的嗎？
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ALaunos治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ALaunos治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧